Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4 (NASDAQ:PHAT)
Phathom Pharma (PHAT) Q2 2026 earnings call: VOQUEZNA growth, first operating profit, lower revenue guidance on payer friction, and pipeline updatesâread...
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Phathom Pharma (PHAT) Q2 2026 earnings call: VOQUEZNA growth, first operating profit, lower revenue guidance on payer friction, and pipeline updatesâread...
Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4 (NASDAQ:PHAT) | Seeking Alpha
Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2026
Management View
"For the first time in Phathom's history and ahead of our guidance, we generated positive operating profit in Q2, excluding stock-based compensation." (CEO, President & Director Steven Basta)
"For full
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Quick Insights
What are the key risks to Phathom Pharmaceuticals' VOQUEZNA revenue growth?
The main risks are physician and payer friction limiting prescribing, competitive uncertainty from new entrants, and possible hesitation due to perceived hurdles despite operational efforts to streamline workflows.
How is Phathom Pharmaceuticals addressing physician and payer workflow friction for VOQUEZNA?
Phathom is focused on incremental efficiency improvements, leveraging omnichannel investment, streamlining prior authorization with Blink support, and supporting high prescribers, as well as highlighting coverage and operational enhancements.
What is the financial outlook and profitability trajectory for Phathom Pharmaceuticals?
Phathom updated its revenue guidance to $310-$325 million for the year, achieved its first operating profit (excluding stock-based compensation) ahead of schedule, expects sustained profitability, and aims for durable cash flow positivity in 2027, while OpEx guidance incorporates planned pipeline investments.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.
Sidus Fortis VPX Commercial Launch in 2027 Backed by $158.5M Funding
Sidus Space announces the commercial availability of its Fortis VPX edge computing module by early 2027, supported by $158.5M raised in Q2 2025. Learn about its technology advantages, market outlook, and financial health.
TOMI Reaffirms 2026 Revenue Guidance of at Least $12M, Sets $10M Funding Goal for Carbonium Core Merger
TOMI Environmental Solutions reaffirms its 2026 revenue guidance of at least $12 million and advances its merger with Carbonium Core, targeting $10 million in funding. This article analyzes the strategic implications, industry context, and potential risks.
